US drugmaker Endo International (Nasdaq: ENDP) saw its shares fall 6.7% to $26.54 in early trading on Thursday, after the USA’s competition regulator sued the company for violating antitrust regulations.
The US Federal Trade Commission filed a complaint in federal district court alleging that Endo Pharmaceuticals and several other drug companies violated antitrust laws by using pay-for-delay settlements to block consumers’ access to lower-cost generic versions of Opana ER (oxymorphone hydrochloride) extended-release tablets and Lidoderm (lidocaine patch 5%).
Following more than a decade of FTC challenges to pay-for-delay settlements, today’s enforcement action is the first FTC case challenging an agreement not to market an authorized generic – often called a “no-AG commitment” – as a form of reverse payment, the regulator pointed out.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze